Brazil, understood as an operating environment.
Brazil is not one market. It is a continental clinical system with distinct regulatory, institutional and reimbursement dynamics. We navigate it as insiders.
Brazil holds unmatched phenotypic diversity, world-class tertiary centers and a public health system covering more than 200 million lives — yet remains structurally underused for rare disease innovation.
Phenotypic diversity
A population that broadens signal detection across rare presentations.
Tertiary medical excellence
Centers whose investigators publish at international standards.
Scale of care
SUS coverage that enables meaningful cohort discovery.
Real-world evidence potential
Longitudinal data sources when governed correctly.
Eight steps from disease landscape to long-term adoption.
- 01
Understand the disease landscape
Epidemiology, natural history, existing clinical experience.
- 02
Identify physicians and centers
Specialists and institutions with real disease-area expertise.
- 03
Map potential patient cohorts
Phenotypic and geographic mapping of relevant populations.
- 04
Evaluate regulatory and access pathways
ANVISA, CONITEC, RENAME, expanded and compassionate use.
- 05
Generate local evidence
Real-world data and Brazilian clinical credibility.
- 06
Engage institutions and stakeholders
Academic, public-sector and private-sector alignment.
- 07
Structure access and development opportunities
Early access, clinical collaboration and evidence generation.
- 08
Build the long-term adoption pathway
Reimbursement, distribution and continuity of care.
Real-world evidence generated with Brazilian rigor supports both access decisions and international regulatory dossiers.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.